In Vivo Efficacy/Disease Models
Caliper’s contract research arm, CDAS (Caliper Discovery Alliances & Services) has long recognized the value that data obtained from validated animal models can bring to preclinical drug discovery research. Over the years, many approved drugs for use in humans were first shown to demonstrate efficacy in rodent models – Enbrel®, Singulair®, Zoloft®, Lipitor®, Capoten®, Evista® and Fosomax®, just to name a few.
Determining a compound’s efficacy profile is the focus of our comprehensive In Vivo Compound Profiling program – a customized battery of pharmacological bioassays (measuring over 450 parameters relevant to 15 therapeutic areas). This platform also offers direct disease-related physiological and behavioral endpoints for in vivo assessment. Various subsets of all available assays are used to (i) assess the therapeutic efficacy of optimized lead compounds and/or drug development candidates by analyzing their effects on key physiological functions in animals, (ii) screen for potential side effects caused by the administration of such compounds, and/or (iii) discover secondary indications for such compounds that were not previously known or suspected, thus expanding the market potential of those drug candidates.
The program leverages our proprietary optical imaging (i.e., bioluminescent and/or fluorescent) technology to characterize mechanism of action parameters or anti-tumor properties of submitted compounds. Moreover, we expect that this program’s greatest impact will be to expand the market potential of certain drug or drug candidates through the discovery of critically important secondary or additional indications for marketed as well as for preclinical/clinical drug development candidates.
The In Vivo Compound Profiling platform includes over 85 standardized and validated bioassays covering many therapeutic areas, including allergic diseases, arthritis, cardiovascular diseases, diabetes, gastrointestinal disorders, immunology and inflammation, neurodegenerative disorders, oncology, obesity, osteoporosis, pain, psychiatric disorders, sexual health, tissue repair and urological disorders.
Key highlights of the platform include:
- Choice of route of administration for test compounds (i.e., oral gavage, oral with diet, i.p., i.v., i.m., s.c., or topical)
- Choice of acute or chronic dosing paradigms
- Ability to determine MOA insights by leveraging physiological challenge bioassays associated with our proprietary in vivo bioluminescent/fluorescent imaging technology
- Access to a very cost-effective program for comprehensive profiling of any drug development candidate
Not only does CDAS regularly add new assays to its portfolio, but we will customize a compound profiling program tailored to meet your discovery research objectives.
